Showing results (1251-1260 of 1,400) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|October 30, 2018
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant MesotheliomaLiang Cao, Yunkai Yu, Anish Thomas, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
JCO Precision Oncology|July 21, 2022
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse EventsMirjam de With, Gemma Brufau, Laila A van den Berg, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
JCO Precision Oncology|June 12, 2018
Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer SubtypesDadi Jiang, Brandon Turner, Jie Song, et al.
JCO Precision Oncology|August 28, 2018
Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse MalignanciesShumei Kato, Jeffrey S Ross, Laurie Gay, et al.
JCO Precision Oncology|January 26, 2023
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid TumorsApostolia Maria Tsimberidou, Henry Hiep Vo, Jennifer Beck, et al.
JCO Precision Oncology|August 20, 2025
Sociodemographic Features, Health Care Costs, and Treatment Implications of Genomic Classifier Testing for Localized Prostate Cancer in the United StatesJames R Janopaul-Naylor, Dattatraya Patil, Shreyas Joshi, et al.
JCO Precision Oncology|March 17, 2023
Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in VeteransKatherine I Zhou, Vishal Vashistha, Aixia Guo, et al.
JCO Precision Oncology|August 11, 2022
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor InhibitorsHiroki Sato, Daisuke Kubota, Huan Qiao, et al.
Pageof 140